A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Burgas, Bulgarije
- Alkermes Investigational Site
-
Kazanlak, Bulgarije
- Alkermes Investigational Site
-
Novi Iskar, Bulgarije
- Alkermes Investigational Site
-
Pazardzhik, Bulgarije
- Alkermes Investigational Site
-
Pleven, Bulgarije
- Alkermes Investigational Site
-
Plovdiv, Bulgarije
- Alkermes Investigational Site
-
Radnevo, Bulgarije
- Alkermes Investigational Site
-
Ruse, Bulgarije
- Alkermes Investigational Site
-
Sofia, Bulgarije
- Alkermes Investigational Site
-
Stara Zagora, Bulgarije
- Alkermes Investigational Site
-
Targovishte, Bulgarije
- Alkermes Investigational Site
-
Veliko Tarnovo, Bulgarije
- Alkermes Investigational Site
-
Vratsa, Bulgarije
- Alkermes Investigational Site
-
-
-
-
-
Cebu City, Filippijnen
- Alkermes Investigational Site
-
Iloilo City, Filippijnen
- Alkermes Investigational Site
-
Mandaluyong City, Filippijnen
- Alkermes Investigational Site
-
Manila, Filippijnen
- Alkermes Investigational Site
-
Pasig City, Filippijnen
- Alkermes Investigational Site
-
-
Bataan
-
Mariveles, Bataan, Filippijnen
- Alkermes Investigational Site
-
-
-
-
-
Jeju-si, Korea, republiek van
- Alkermes Investigational Site
-
Jeollanam-do, Korea, republiek van
- Alkermes Investigational Site
-
Seoul, Korea, republiek van
- Alkermes Investigational Site
-
-
-
-
-
Cheras, Maleisië
- Alkermes Investigational Site
-
Johor Bahru, Maleisië
- Alkermes Investigational Site
-
Kuala Lumpur, Maleisië
- Alkermes Investigational Site
-
Kuching, Maleisië
- Alkermes Investigational Site
-
-
-
-
-
Chernigiv, Oekraïne
- Alkermes Investigational Site
-
Donetsk, Oekraïne
- Alkermes Investigational Site
-
Kharkiv, Oekraïne
- Alkermes Investigational Site
-
Kyiv, Oekraïne
- Alkermes Investigational Site
-
Lugansk, Oekraïne
- Alkermes Investigational Site
-
Lviv, Oekraïne
- Alkermes Investigational Site
-
Poltava, Oekraïne
- Alkermes Investigational Site
-
Simferopol, Oekraïne
- Alkermes Investigational Site
-
Ternopil, Oekraïne
- Alkermes Investigational Site
-
Uzhgorod, Oekraïne
- Alkermes Investigational Site
-
Vinnytsya, Oekraïne
- Alkermes Investigational Site
-
-
Kherson
-
Stepanovka, Kherson, Oekraïne
- Alkermes Investigational Site
-
-
-
-
-
Bucharest, Roemenië, 030455
- Alkermes Investigational Site
-
Bucharest, Roemenië
- Alkermes Investigational Site
-
Craiova, Roemenië
- Alkermes Investigational Site
-
Iasi, Roemenië
- Alkermes Investigational Site
-
Targu Mures, Roemenië
- Alkermes Investigational Site
-
-
Bihor
-
Oradea, Bihor, Roemenië
- Alkermes Investigational Site
-
-
-
-
-
Lipetsk, Russische Federatie
- Alkermes Investigational Site
-
Moscow, Russische Federatie
- Alkermes Investigational Site
-
Nizhniy Novgorod, Russische Federatie
- Alkermes Investigational Site
-
Rostov-on-Don, Russische Federatie
- Alkermes Investigational Site
-
Samara, Russische Federatie
- Alkermes Investigational Site
-
Saratov, Russische Federatie
- Alkermes Investigational Site
-
St. Petersburg, Russische Federatie
- Alkermes Investigational Site
-
Stavropol, Russische Federatie
- Alkermes Investigational Site
-
Voronezh, Russische Federatie
- Alkermes Investigational Site
-
Yaroslavl, Russische Federatie
- Alkermes Investigational Site
-
-
Gatchinckiy
-
Nikol'skoye, Gatchinckiy, Russische Federatie
- Alkermes Investigational Site
-
-
Orenburg
-
Staritsa, Orenburg, Russische Federatie
- Alkermes Investigational Site
-
-
Primorsky
-
Talagi, Primorsky, Russische Federatie
- Alkermes Investigational Site
-
-
Sergievo-Posadskiy
-
Khotkovo, Sergievo-Posadskiy, Russische Federatie
- Alkermes Investigational Site
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72201
- Alkermes Investigational Site
-
Little Rock, Arkansas, Verenigde Staten, 72211
- Alkermes Investigational Site
-
Springdale, Arkansas, Verenigde Staten, 72764
- Alkermes Investigational Site
-
-
California
-
Cerritos, California, Verenigde Staten, 90703
- Alkermes Investigational Site
-
Garden Grove, California, Verenigde Staten, 92845
- Alkermes Investigational Site
-
La Habra, California, Verenigde Staten, 90631
- Alkermes Investigational Site
-
Oakland, California, Verenigde Staten, 94612
- Alkermes Investigational Site
-
Oceanside, California, Verenigde Staten, 92056
- Alkermes Investigational Site
-
Orange, California, Verenigde Staten, 92868
- Alkermes Investigational Site
-
San Diego, California, Verenigde Staten, 92123
- Alkermes Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, Verenigde Staten, 20016
- Alkermes Investigational Site
-
-
Florida
-
Fort Lauderdale, Florida, Verenigde Staten, 33308
- Alkermes Investigational Site
-
Leesburg, Florida, Verenigde Staten, 34748
- Alkermes Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30308
- Alkermes Investigational Site
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60640
- Alkermes Investigational Site
-
Hoffman Estates, Illinois, Verenigde Staten, 60169
- Alkermes Investigational Site
-
-
Kansas
-
Overland Park, Kansas, Verenigde Staten, 66212
- Alkermes Investigational Site
-
-
Maryland
-
Rockville, Maryland, Verenigde Staten, 20850
- Alkermes Investigational Site
-
-
Missouri
-
Creve Coeur, Missouri, Verenigde Staten, 63141
- Alkermes Investigational Site
-
Saint Louis, Missouri, Verenigde Staten, 63118
- Alkermes Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19139
- Alkermes Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29407
- Alkermes Investigational Site
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78731
- Alkermes Investigational Site
-
Austin, Texas, Verenigde Staten, 78754
- Alkermes Investigational Site
-
Dallas, Texas, Verenigde Staten, 75231
- Alkermes Investigational Site
-
Dallas, Texas, Verenigde Staten, 75243
- Alkermes Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosis of schizophrenia according to DSM-IV-TR criteria
- Has been able to achieve outpatient status for more than 3 months in the past year
- Body mass index (BMI) of 18.5 to 40.0 kg/m2 (inclusive)
- Resides in a stable living situation
- Willing and able to be confined to an inpatient study unit for 2 weeks or longer
Exclusion Criteria:
- History of poor or inadequate clinical response to treatment with aripiprazole
- History of treatment resistance
- Known or suspected intolerance of, allergy, or hypersensitivity to aripiprazole, its ingredients, other antipsychotic agent, or INTRALIPID (including peanuts, soy, egg, or glycerol)
- Diagnosis of current substance dependence (including alcohol)
- Pregnant, lactating, or breastfeeding
- Receipt of any antipsychotic medication by IM injection within 60 days before Screening
- Current involuntary hospitalization or incarceration
- Hospitalized for more than 30 days during the 90 days before Screening
Additional inclusion/exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
|
Placebo for IM injection, given monthly
|
|
Experimenteel: ALKS 9072
|
Intramuscular (IM) injection, 441 mg or 882 mg given monthly
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score
Tijdsspanne: Data collected from baseline to day 85
|
The PANSS scale contains 30 questions, each containing an answer range of 1-7.
A total PANSS score can range from between 30 to 210; a higher score indicates a worse disease condition.
|
Data collected from baseline to day 85
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Clinical Global Impression - Improvement (CGI-I) Scores at Day 85
Tijdsspanne: 85 Days
|
The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the study.
Results indicate participants evaluated at one of the following categories: "1: very much improved"; "2: much improved"; "3: minimally improved"; "4: no change"; "5: minimally worse"; "6: much worse"; or "7: very much worse".
|
85 Days
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Targum SD, Risinger R, Du Y, Pendergrass JC, Jamal HH, Silverman BL. Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. Schizophr Res. 2017 Jan;179:64-69. doi: 10.1016/j.schres.2016.09.034. Epub 2016 Oct 1.
- Nasrallah HA, Newcomer JW, Risinger R, Du Y, Zummo J, Bose A, Stankovic S, Silverman BL, Ehrich EW. Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. J Clin Psychiatry. 2016 Nov;77(11):1519-1525. doi: 10.4088/JCP.15m10467.
- Citrome L, Du Y, Risinger R, Stankovic S, Claxton A, Zummo J, Bose A, Silverman BL, Ehrich EW. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. Int Clin Psychopharmacol. 2016 Mar;31(2):69-75. doi: 10.1097/YIC.0000000000000106.
- Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, Bose A, Stankovic S, Silverman BL, Ehrich EW. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015 Aug;76(8):1085-90. doi: 10.4088/JCP.14m09741.
- Potkin SG, Risinger R, Du Y, Zummo J, Bose A, Silverman B, Stankovic S, Ehrich E. Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. Schizophr Res. 2017 Dec;190:115-120. doi: 10.1016/j.schres.2017.03.003. Epub 2017 Mar 23.
- Cameron C, Zummo J, Desai DN, Drake C, Hutton B, Kotb A, Weiden PJ. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison. Value Health. 2017 Jul-Aug;20(7):876-885. doi: 10.1016/j.jval.2017.03.010. Epub 2017 May 9.
- Citrome L, Risinger R, Cutler AJ, Du Y, Zummo J, Nasrallah HA, Silverman BL. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study. CNS Spectr. 2018 Aug;23(4):284-290. doi: 10.1017/S1092852917000396. Epub 2017 Jun 19.
- Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia. J Clin Psychopharmacol. 2017 Jun;37(3):289-295. doi: 10.1097/JCP.0000000000000691.
- Cameron C, Zummo J, Desai D, Drake C, Hutton B, Kotb A, Weiden PJ. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies. Curr Med Res Opin. 2018 Apr;34(4):725-733. doi: 10.1080/03007995.2017.1410471. Epub 2018 Jan 10.
- McEvoy JP, Risinger R, Mykhnyak S, Du Y, Liu CC, Stanford AD, Weiden PJ. Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia. J Clin Psychiatry. 2017 Sep-Oct;78(8):1103-1109. doi: 10.4088/JCP.17m11625.
Studie record data
Bestudeer belangrijke data
Studie start
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- ALK9072-003
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .